Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Nasopharyngeal Cancer
Powered by
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Nasopharyngeal Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.
Bevacizumab in Nasopharyngeal Cancer Drug Details:
Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It is formulated as solution, concentrate solution for intravenous route of administration. Avastin in combination with xeloda or paclitaxel is indicated for the treatment of metastatic breast cancer. In combination with cisplatin (or carboplatin) and etoposide, bevacizumab is indicated for the treatment of small-cell lung cancer. Avastin is used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer (with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease) and glioblastoma, with interferon alfa. Avastin in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer, malignant glioma. It is also indicated for the treatment of persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. In combination with paclitaxel it is used for the treatment of platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also indicated for the treatment of cervical cancer with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy). Avastin is also indicated in combination with chemotherapy, to treat patients with recurrent ovarian cancer (Advanced Ovarian cancer). Avastin either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and in combination with atezolizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Avastin in combination with atezolizumab is indicated for the treatment unresectable hepatocellular carcinoma.Bevacizumab (RG435) is under development for the treatment of metastatic hepatocellular carcinoma, non-small cell lung cancer, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma (first and second line therapy), as first line therapy for epithelial ovarian, fallopian tube, primary peritoneal cancer and hepatocellular carcinoma, locally advanced/metastatic well-differentiated digestive endocrine tumors, urothelial cell carcinoma, malignant mesothelioma, melanoma as first line and second line therapy, nasopharyngeal carcinoma, appendiceal adenocarcinoma, relapsed or refractory neuroblastoma (second line), adjuvant breast cancer (BC) HER2 negative, oligodendroglioma, metastatic breast cancer first and second line therapy, epithelial ovarian, bile duct cancer (first line), endocrine tumors of the gastrointestinal tract, and renal cell carcinoma in Japan. Avastin in combination with Tarceva (erlotinib) is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. It is also indicated in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian and non-small cell lung cancer. It is under development for the treatment of recurrent glioblastoma multiforme and malignant pleural mesothelioma. It is also under development for anal cancer, cervical cancer, vulvar cancer, vaginal cancer and penile cancer.It was also under development for non metastatic bladder cancer, HER2+ breast cancer, adjuvant non small cell lung cancer (NSCLC), metastatic liver cancer, chronic lymphocytic leukemia (CLL), intracranial meningioma, endometrial cancer, neuroendocrine carcinoid carcinoma, locally advanced and/or metastatic pancreatic cancer, cervical cancer, relapsed/refractory multiple myeloma and for diffuse large B-cell lymphoma and as adjuvant therapy for HER2 positive breast cancer, glioblastoma multiforme first line and metastatic rhabdomyosarcoma, metastatic renal cell carcinoma and non-rhabdomyosarcoma soft tissue sarcoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
Quick View – Bevacizumab LOA Data | |||||
Report Segments |
|
||||
Drug Name |
|
||||
Administration Pathway |
|
||||
Therapeutic Areas |
|
||||
Key Manufacturers |
|
||||
Drug Development Status |
|
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently asked questions
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
- Phase I, Phase II, Phase III, and Pre-Registration development stage
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
- Innovator drugs and biosimilars
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
Inclusion
Data Scope:
Drug Phase Scope:
Drug Geography Scope:
Drug Type Scope:
Entity Type Scope:
Only drugs in development by companies are included in the model.
Exclusion
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745